Q32 Bio grants 10,826 stock options to director

Q32 Bio Inc. director Arthur Tzianabos reported a corrected grant of 10,826 stock options to acquire Common Stock, awarded on June 12, 2026 at an exercise price of $12.64 per share and expiring on June 11, 2036.

Rhea-AI Filing Summary

Q32 Bio Inc. director Arthur Tzianabos reported a corrected grant of 10,826 stock options to acquire Common Stock, awarded on June 12, 2026 at an exercise price of $12.64 per share and expiring on June 11, 2036. The options vest and become exercisable in full on the earlier of June 12, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. This amendment updates a Form 4 filed on June 16, 2026 solely to correct the number of options awarded.

Insider Trade Summary

Grant/Award: 10,826 shares

Grant/Award 1 txn

Insider TZIANABOS ARTHUR

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	10,826	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 10,826 contracts (Direct)

Footnotes (2)

1. F1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
2. F2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Key Figures

Options Granted: 10,826 options Exercise Price: $12.64 per share Expiration Date: June 11, 2036 +2 more

5 metrics

Options Granted 10,826 options Stock Option (Right to Buy) granted to director on June 12, 2026

Exercise Price $12.64 per share Conversion or exercise price of the stock option award

Expiration Date June 11, 2036 Option expiration for the 10,826 stock options granted

Vesting Trigger Date June 12, 2027 Earlier of this date or next annual meeting, subject to continued service

Post-Transaction Options Held 10,826 options Total options from this award following the reported grant

Key Terms

Stock Option (Right to Buy), Common Stock, annual meeting of stockholders, vest and become exercisable

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

annual meeting of stockholders financial

"the date of the Issuer's next annual meeting of stockholders"

vest and become exercisable financial

"shares underlying this option shall vest and become exercisable in full"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Q32 Bio Inc. (QTTB) report in this amended Form 4?

Q32 Bio Inc. reported a stock option grant to director Arthur Tzianabos. He received 10,826 options to acquire Common Stock, with specific vesting terms and an exercise price detailed as part of his director compensation.

How many stock options were granted to Arthur Tzianabos in QTTB’s latest filing?

Arthur Tzianabos was granted 10,826 stock options. The amended filing states this figure corrects the number of options originally reported, and reflects his total option holdings from this award following the transaction.

What is the exercise price and expiration date of the QTTB options granted to Arthur Tzianabos?

The options granted to Arthur Tzianabos have an exercise price of $12.64 per share and an expiration date of June 11, 2036, defining the price and time window during which they may be exercised once vested.

What are the vesting terms of the 10,826 QTTB stock options granted to Arthur Tzianabos?

The 10,826 options vest and become exercisable in full on the earlier of June 12, 2027 or the date of Q32 Bio’s next annual meeting of stockholders, provided Arthur Tzianabos continues his service through the applicable vesting date.

Why did Q32 Bio Inc. (QTTB) file an amended Form 4 for Arthur Tzianabos?

The company filed this amendment solely to correct the number of options reported as awarded on June 12, 2026. The earlier Form 4 filed on June 16, 2026 contained an incorrect option count for this grant.

Was the QTTB option grant to Arthur Tzianabos reported under a Rule 10b5-1 trading plan?

The Rule 10b5-1 checkbox in the filing is not marked, so this grant is not identified as made pursuant to a Rule 10b5-1 trading plan, and instead appears as a standard director equity award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/21/2026 - 08:40 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TZIANABOS ARTHUR

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/16/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$12.64	06/12/2026		A		10,826(1)		(2)	06/11/2036	Common Stock	10,826(1)	$0	10,826(1)	D

Explanation of Responses:

1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.

2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

	/s/ Eric Bell, Attorney-in-Fact	07/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)